Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion. Fair value range: low $55.9, high $85.0, with mid-point at $70.4.
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.
§1 Sintesi
Strong Buy rating driven by 30% upside to $70.39 composite fair value midpoint.
Mature compounder profile translates high ROE into durable EPS growth with fading downside risk.
Q1 revenue growth of 11.6% outpaces major cardiovascular and MedSurg peers.
Valuation explicitly bridges benchmark optimism with structural terminal constraints via a moat-fade framework.
Fair value
$70
Margin of safety
+23.1%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$54.10Price
Low $55.91
Mid $70.39
High $85.05
Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion.
High switching costs in implantable
High switching costs in implantable MedSurg devices.
Intangible assets via robust IP
Intangible assets via robust IP in structural heart (WATCHMAN).
Based on our latest analysis, BSX looks meaningfully undervalued. The current price is $54.1 versus a composite fair-value midpoint of $70.4 (range $55.9–$85.0), which implies roughly 30.1% upside to the midpoint.
Our composite fair-value range for BSX is $55.9–$85.0, with a midpoint of $70.4. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for BSX's archetype.
Our current rating for BSX is Strong Buy with a confidence score of 88/100. Strong-buy. The composite fair value of $70.39 effectively bridges internal valuation cross-check optimism with internal fundamental constraints, supported by reliable discounted earnings models. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for BSX are: Multiple Compression to Peer Median; Reimbursement Rate Cuts; WATCHMAN Normalization Stall. The single biggest risk is Multiple Compression to Peer Median: Premium valuation collapses as the market forces reversion to peer median PEG ratios.
Our current rating for BSX is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($55.9–$85.0) versus the current price of $54.1.
BSX is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for BSX.
